Tumor biology - Herceptin acts as an anti-angiogenic cocktail
Tumor biology - Herceptin acts as an anti-angiogenic cocktail
复制标题
DOI：
10.1038/416279b
复制
发表时间：
2002-03-21
期刊：
影响因子：
64.8
通讯作者：
Jain, RK
中科院分区：
文献类型：
--
作者：
Izumi, Y;Xu, L;Jain, RK
恶性肿瘤会分泌一些因子，使它们能够控制自己的血液供应（血管生成），阻断这些因子的作用可以抑制肿瘤的生长。但是，由于肿瘤可能会对靶向单个血管生成因子的治疗产生抗药性，因此通过切换到其他血管生成分子，多种抗血管生成剂的鸡尾酒应该更有效。在这里，我们表明，赫赛汀，一种单克隆抗体对细胞表面受体HER 2（人表皮生长因子受体-2;参考），诱导正常化和退化的血管在一个实验性的人类乳腺肿瘤，过度表达HER 2的小鼠，它的工作原理是通过调节不同的促血管生成和抗血管生成因子的影响。作为一种针对多个靶点的单一药物，赫赛汀或类似药物可能提供了组合抗血管生成治疗的简单替代方案。
Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules,, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. ), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.